Halozyme Therapeutics, Inc. (HALO)
63.43
+0.16
(+0.25%)
USD |
NASDAQ |
Mar 20, 16:00
63.74
+0.31
(+0.49%)
After-Hours: 20:00
Halozyme Therapeutics Research and Development Expense (Quarterly) : 31.90M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 4.268B |
| Skye Bioscience, Inc. | 11.29M |
| Eli Lilly & Co. | 3.802B |
| Stryker Corp. | 380.00M |
| Glaukos Corp. | 43.65M |